Selective Laser Trabeculoplasty and the Evolving Glaucoma Treatment Paradigm (CE Webinar)
Activity Description and Purpose
Medical therapy has been the mainstay of first-line glaucoma treatment for more than 150 years. Recent advances, including selective laser trabeculoplasty (SLT), sustained-release drug delivery platforms, and minimally invasive glaucoma surgeries, have expanded the treatment options. New data from the LiGHT (Laser in Glaucoma and Ocular Hypertension) study and others support the role of SLT as preferred first-line therapy over medications. COAST (Clarifying the Optimal Application of SLT Therapy) is an ongoing multicenter clinical trial supported by the National Institutes of Health/National Eye Institute to evaluate the role of annual low-energy SLT as primary therapy for glaucoma. This educational activity will briefly review the historical context that shaped the medications-first treatment paradigm, discuss limitations of medical therapy and emerging data supporting an SLT-first approach to glaucoma care, and present a novel interventional paradigm for the management of glaucoma in 2023 and beyond.
This educational activity is intended for optometrists.
After completing this activity, participants will be better able to:
- Describe the current medication-first glaucoma treatment paradigm and its important limitations
- Discuss the emerging evidence supporting the role of SLT as primary therapy for glaucoma
- Explain the rationale for a paradigm shift to early interventional glaucoma therapy starting with SLT
|Tony Realini, MD, MPH
Professor and Vice Chair for Clinical Research
West Virginia University
Morgantown, West Virginia
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.
Tony Realini, MD, is a consultant for iSTAR Medical*, Ivantis Inc*, New World Medical, Inc, Ocular Therapeutix, Inc, Oyster Point Pharma, Inc, and Sight Sciences.
* The financial relationship existed during the last 24 months but has now ended
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
COPE approved for 1.0 CE credit for optometrists.
COPE Course ID: 85610-GL (Synchronous Virtual)
COPE Course Category: Glaucoma
Disclosure of Commercial Support
This continuing education activity has no commercial support. The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC.
©2023 MedEdicus LLC. 310
- 1.00 COPE